Literature DB >> 31601653

A New Escherichia coli Entry Vector Series (pIIS18) for Seamless Gene Cloning Using Type IIS Restriction Enzymes.

Hend Altaib1, Yuka Ozaki2, Tomoya Kozakai1, Yassien Badr2,3, Izumi Nomura2, Tohru Suzuki4,2.   

Abstract

A series of new Escherichia coli entry vectors (pIIS18-SapI, pIIS18-BsmBI, pIIS18-BsaI, pIIS18-BfuAI-1, and pIIS18-BfuAI-2) was constructed based on a modified pUC18 backbone, which carried newly designed multiple cloning sites, consisting of two facing type IIS enzyme cleavage sites and one blunt-end enzyme cleavage site. These vectors are useful for seamless gene cloning.
Copyright © 2019 Altaib et al.

Entities:  

Year:  2019        PMID: 31601653      PMCID: PMC6787310          DOI: 10.1128/MRA.00323-19

Source DB:  PubMed          Journal:  Microbiol Resour Announc        ISSN: 2576-098X


ANNOUNCEMENT

The plasmid construction in Escherichia coli is one of the essential routine works in the field of molecular biology (1, 2). The seamless (or scarless) gene cloning technique is an important tool for precise assembly of DNA fragments which leaves no additional linker sequence between assembled fragments. This method enables the creation of an ideal condition for precise functional studies, such as mutation study, gene fusion, and genome engineering (3, 4). Recently, the seamless cloning techniques, such as Golden Gate cloning (GGC) (5, 6) and Gibson assembly (7), have been developed and widely used in various genetic engineering applications. Type IIS restriction enzymes recognize a 5- to 8-bp asymmetrical sequence and cleave outside the recognition sequence (8). This unique feature fits for the seamless cloning method and is used in GGC. Usually, PCR-amplified fragments are used for GGC or other seamless cloning techniques. However, each fragment needs 10 or more excess bases to be added at the 5′ end of each primer (Fig. 1C), which may disturb PCR amplification. Using a PCR fragment, it also needs to confirm the DNA sequence to obtain a correct clone because the DNA polymerases do not have 100% fidelity.
FIG 1

(A) Molecular structure of pIIS18-SapI cloning vector series, showing genes on the plasmid backbone. The removed type IIS enzyme cleavage sites from pUC18 are marked with parentheses on the plasmid map. The MCS structure is illustrated within the lacZ′ gene. The DNA linkers inserted into the MCS of each plasmid construct are demonstrated. Each linker carries one blunt-end enzyme and two facing type IIS enzyme cleavage sites located between PstI and BamHI sites. (B) Model for usage of the pIIS18 entry vector, demonstrating the insertion of a 3-bp tagged PCR product within the blunt-end-cleaved pIIS18-SapI. Once a fragment is inserted in pIIS18, it can be sequence verified and then become a ligation-ready part. (C) Original GGC, in which PCR errors make it possible to get a mutated construct; hence, it requires multiple proof sequence reads to find out the correct construct and requires multiple primer design. (D) GGC with pIIS18, in which PCR errors were eliminated through an additional cloning and sequencing step before GGC. The additional step removes the possibility of PCR error construct and allows the multiple usage of sequence-verified DNA parts several times. Few sequence reads will be needed just to confirm fragment order in the final construct.

(A) Molecular structure of pIIS18-SapI cloning vector series, showing genes on the plasmid backbone. The removed type IIS enzyme cleavage sites from pUC18 are marked with parentheses on the plasmid map. The MCS structure is illustrated within the lacZ′ gene. The DNA linkers inserted into the MCS of each plasmid construct are demonstrated. Each linker carries one blunt-end enzyme and two facing type IIS enzyme cleavage sites located between PstI and BamHI sites. (B) Model for usage of the pIIS18 entry vector, demonstrating the insertion of a 3-bp tagged PCR product within the blunt-end-cleaved pIIS18-SapI. Once a fragment is inserted in pIIS18, it can be sequence verified and then become a ligation-ready part. (C) Original GGC, in which PCR errors make it possible to get a mutated construct; hence, it requires multiple proof sequence reads to find out the correct construct and requires multiple primer design. (D) GGC with pIIS18, in which PCR errors were eliminated through an additional cloning and sequencing step before GGC. The additional step removes the possibility of PCR error construct and allows the multiple usage of sequence-verified DNA parts several times. Few sequence reads will be needed just to confirm fragment order in the final construct. Several expression vectors have become available for GGC and other seamless cloning techniques. In this paper, we focused on constructing a new series of entry vectors, pIIS18-SapI, pIIS18-BsmBI, pIIS18-BsaI, pIIS18-BfuAI-1, and pIIS18-BfuAI-2. Each vector carries a newly designed multiple cloning site (MCS) on a modified pUC18 backbone (1, 9). We constructed this plasmid series as described below. Five different series of DNA linkers were designed to include two facing type IIS enzyme cleavage sites (SapI, BsmBI, BsaI, or BfuAI) and one blunt-end enzyme cleavage site (EcoRV, Bsp68I, or SwaI) (Fig. 1A). Each design retains the same reading frame of the β-galactosidase gene (lacZ′). pUC18 carries two BsmBI sites, one SapI site, and one BsaI site within its backbone. We have removed these sites using site-directed mutagenesis. This will prevent jamming (incorrect) religation in case of the one-pot reaction of GGC (Fig. 1D) (5). For pIIS18-SapI construction, pUC18 was doubly digested with PstI and BamHI. The linearized pUC18 was purified and ligated with the SapI DNA linker (Fig. 1A). The obtained ligation product was introduced to E. coli DH5α chemically competent cells (Nippon Gene), following the standard protocol, and colonies were selected on an LB agar plate supplemented with ampicillin (100 μg/ml) and 2% X-Gal (5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside). The modified construct (within blue colonies) was confirmed by successful cleavage with SapI or Bsp68I and whole-plasmid sequencing using the BigDye Terminator ver. 3.1 cycle sequencing kit. The sequence data were analyzed using an ABI 3130xl genetic analyzer (Thermo Fisher Scientific, Inc.). The other four pIIS18 vector models have been constructed in the same way as pIIS18-SapI. pIIS18 series are designed for type IIS restriction enzyme-mediated seamless gene fusion, such as GGC (Fig. 1D). They allow for direct sequence analysis of a cloned DNA fragment with just a single primer set annealing to the plasmid backbone before seamless ligation (Fig. 1B). The mutation rate during the ligation and transformation reactions is practically ignorable. The pIIS18 series will be helpful for molecular biologists, especially in experiments requiring DNA sequence verification, such as multigene fusion (Fig. 1D), and systematic construction of mutants.

Data availability.

The complete sequences of pIIS18-SapI, pIIS18-BsmBI, pIIS18-BsaI, pIIS18-BfuAI-1, and pIIS18-BfuAI-2 have been deposited in the DNA Data Bank of Japan under the accession numbers LC459971 to LC459975, respectively. The resource can be obtained from the Addgene depository (https://www.addgene.org/) and the GCMR library of Gifu University (https://www1.gifu-u.ac.jp/~g_cmr/index.html). The raw sequencing reads are available at https://www1.gifu-u.ac.jp/~suzuki/pIIS_plasmids/.
  9 in total

Review 1.  Impact of targeted vector design on Co/E1 plasmid replication.

Authors:  Reingard Grabherr; Karl Bayer
Journal:  Trends Biotechnol       Date:  2002-06       Impact factor: 19.536

2.  Golden Gate cloning.

Authors:  Carola Engler; Sylvestre Marillonnet
Journal:  Methods Mol Biol       Date:  2014

3.  New high-cloning-efficiency vectors for complementation studies and recombinant protein overproduction in Escherichia coli and Salmonella enterica.

Authors:  C M VanDrisse; J C Escalante-Semerena
Journal:  Plasmid       Date:  2016-05-24       Impact factor: 3.466

4.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

Authors:  C Yanisch-Perron; J Vieira; J Messing
Journal:  Gene       Date:  1985       Impact factor: 3.688

5.  Characterizing seamless ligation cloning extract for synthetic biological applications.

Authors:  Katrin Messerschmidt; Lena Hochrein; Daniel Dehm; Karina Schulz; Bernd Mueller-Roeber
Journal:  Anal Biochem       Date:  2016-06-14       Impact factor: 3.365

6.  Restriction enzyme body doubles and PCR cloning: on the general use of type IIs restriction enzymes for cloning.

Authors:  Eszter Tóth; Krisztina Huszár; Petra Bencsura; Péter István Kulcsár; Barbara Vodicska; Antal Nyeste; Zsombor Welker; Szilvia Tóth; Ervin Welker
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

7.  Enzymatic assembly of overlapping DNA fragments.

Authors:  Daniel G Gibson
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

Review 8.  Seamless cloning and gene fusion.

Authors:  Quinn Lu
Journal:  Trends Biotechnol       Date:  2005-04       Impact factor: 19.536

9.  A one pot, one step, precision cloning method with high throughput capability.

Authors:  Carola Engler; Romy Kandzia; Sylvestre Marillonnet
Journal:  PLoS One       Date:  2008-11-05       Impact factor: 3.240

  9 in total
  3 in total

1.  Structure of a Core Promoter in Bifidobacterium longum NCC2705.

Authors:  Tomoya Kozakai; Ayako Izumi; Ayako Horigome; Toshitaka Odamaki; Jin-Zhong Xiao; Izumi Nomura; Tohru Suzuki
Journal:  J Bacteriol       Date:  2020-03-11       Impact factor: 3.490

2.  Bifidobacterium-Escherichia coli Shuttle Vector Series pKO403, with Temperature-Sensitive Replication Origin for Gene Knockout in Bifidobacterium.

Authors:  Hend Altaib; Yuka Ozaki; Tomoya Kozakai; Kouta Sakaguchi; Izumi Nomura; Tohru Suzuki
Journal:  Microbiol Resour Announc       Date:  2022-01-13

3.  Cell factory for γ-aminobutyric acid (GABA) production using Bifidobacterium adolescentis.

Authors:  Hend Altaib; Tomoya Kozakai; Yassien Badr; Hazuki Nakao; Mahmoud A M El-Nouby; Emiko Yanase; Izumi Nomura; Tohru Suzuki
Journal:  Microb Cell Fact       Date:  2022-03-07       Impact factor: 5.328

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.